insulin and glp-1 agonist combination Schematic illustration of monoagonists, dual agonists triple Combining a GLP-1 receptor agonist
Description
Rhode Island's Medicaid agency proposes ending GLP-1 coverage for weight loss while keeping diabetes uses, citing soaring costs.
A population-based study from Scandinavia provides some real-world information.
Preliminary research indicates they may stop cravings even before people trying to quit feel them.
Explore the mechanisms, clinical applications, and future opportunities of GLP-1 receptor agonists in drug development and disease management.
Starting Wednesday, Medicare will help pay for some GLP-1 medications for weight loss
